Gyre Therapeutics, Inc. Amortization of Debt Issuance Costs
Gyre Therapeutics, Inc. (GYRE) reported Amortization of Debt Issuance Costs of $2.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2025-05-09
- Gyre Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2025-03-31 was $2.00K.
- Gyre Therapeutics, Inc. amortization of debt issuance costs for fiscal 2024 was $9.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|
| 2025-03-31 | $2.00K 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $9.00K 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |